ENTITY
Sihuan Pharmaceutical Hldgs

Sihuan Pharmaceutical Hldgs (460 HK)

50
Analysis
Health CareChina
Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.
more
16 May 2022 08:46

Sihuan Pharmaceutical Hldgs (460.HK)- Privatization Rumor, Upside Potential and Concerns on Business

Sihuan receives attention due to medical aesthetics but it's facing challenges,especially after CBC acquired Hugel.But Sihuan is undervalued, with...

Logo
9.2k Views
Share
13 May 2022 13:17

Sihuan Pharma (460 HK) Denies China Resources Approach

The chairman has recently been selling. He may be interested in selling more.  Sihuan Parma is not expensive.  I'd be picking up shares here on any...

Logo
431 Views
Share
03 Apr 2022 08:48

China Healthcare Weekly (Apr.1)- Lower Budget of Public Hospitals, IPO Environment, Impatient Market

The NHC's budget for 2022 further reduced the expenditure of public hospitals, affecting the payment cycle; For investors in both primary and...

Logo
234 Views
Share
20 Mar 2022 09:05

China Healthcare Weekly (Mar18)-Leaked Document On Medical Service,Biotech Valuation,CE Mark Upgrade

We analyzed the impact of leaked document on medical service. We also analyzed the logic of the reasonable market value of a biotech in HKEX. The...

Logo
247 Views
Share
x